Hayat Biotech to lead conversation on role of biotechnology in healthcare at GITEX

Hayat Biotech to lead conversation on role of biotechnology in healthcare at GITEX

DUBAI, UNITED ARAB EMIRATES: Leading biotech scientist, Dr Nawal Al Kaabi, will today address assembled visitors to GITEX on the protection of societies and drug security, drawing on her personal expertise and experience, and supported by UAE-China partnered Hayat Biotech, where she holds the role of Senior Consultant.

Hayat Biotech is the partnership between Abu Dhabi-based G42 and Sinopharm CNBG, responsible for the manufacture and distribution of the BBiB-CorV inactivated covid-19 vaccine, which has enabled the UAE to become self-sufficient in vaccine supplies. The company is also in the late stages of discussions to supply other neighbouring countries and ensure equitable access to the vaccine.

Dr Al Kaabi will deliver a presentation at the G42 stand today, in her role as Senior Consultant for Hayat Biotech, exploring biotechnology as the present and the future of healthcare. The rapidly evolving science is elevating the medical sector as a whole and providing the tools needed to reduce and fight the rate of infectious diseases, increase knowledge of specific disorders, and increase efficiency in manufacturing processes.

Deputy CEO of Hayat Biotech, Naser Al Yammahi, reinforced this idea, commenting, “Our team of healthcare professionals are united in our desire to pioneer new science-led, technology-based, human-centric solutions. We